Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Colchicine extended release tablet - Pharmascience

Drug Profile

Colchicine extended release tablet - Pharmascience

Alternative Names: Pr MYINFLATM; colchicine 0.5 mg extended-release tablets

Latest Information Update: 25 Dec 2021

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Pharmascience
  • Developer Montreal Heart Institute; Pharmascience
  • Class Anti-ischaemics; Antigouts; Antineoplastics; Colchicum alkaloids; Small molecules; Vascular disorder therapies
  • Mechanism of Action Tubulin polymerisation inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Marketed Coronary artery disease
  • Phase III Myocardial infarction

Most Recent Events

  • 22 Sep 2021 Colchicine extended release tablet is available for licensing as of 22 Sep 2021. https://www.pharmascience.com/canada/contact-us/
  • 22 Sep 2021 Launched for Coronary artery disease (Adjunctive treatment) in Canada (PO)
  • 27 Aug 2021 Efficacy data from the COLCOT phase III trial in Coronary artery disease and Myocardial Infarction released by Pharmascience
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top